Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: Implications for management and age-appropriate testing of relatives at risk

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Objective: To discuss the implications of a young age at diagnosis in a family member with hyperparathyroidism-jaw tumor syndrome, the youngest published case to date, due to a mutation of the CDC73 gene (formerly known as HRPT2); to review this family with regard to modifications of guidelines for surveillance of hyperparathyroidism and other associated features in affected and at-risk relatives; and to discuss surgical recommendations in this syndrome.Methods: A review of English-language publications in PubMed and a review of GeneReviews were conducted pertaining to the subject of familial hyperparathyroidism. A case is described, and the family pedigree is discussed.Results: Review of the literature revealed that CDC73-related disorder has not previously been reported in patients younger than 10 years. This finding has been the basis for the recommendation for initiation of surveillance for disease manifestations at that age. Review of the family history of our current patient revealed a 7-year-old nephew with hypercalcemia attributable to primary hyperparathyroidism.Conclusion: Surveillance of hyperparathyroidism in affected persons and genetic testing of relatives at risk are currently recommended to start at 10 years of age. We recommend that these be conducted at a younger age, preferably 5 to 10 years before the earliest diagnosis of hyperparathyroidism within the family, and potentially at birth in families with a known mutation of the CDC73 gene, in light of the malignant potential of the disease.

Original languageEnglish (US)
Pages (from-to)602-609
Number of pages8
JournalEndocrine Practice
Volume17
Issue number4
DOIs
StatePublished - Jul 1 2011

Fingerprint

Germ-Line Mutation
Hyperparathyroidism
Genes
Mutation
Primary Hyperparathyroidism
Hypercalcemia
Genetic Testing
Pedigree
PubMed
Publications
Early Diagnosis
Language
Parturition
Guidelines

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{087306a29ab44c1ca30262d3b8a2d96c,
title = "Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: Implications for management and age-appropriate testing of relatives at risk",
abstract = "Objective: To discuss the implications of a young age at diagnosis in a family member with hyperparathyroidism-jaw tumor syndrome, the youngest published case to date, due to a mutation of the CDC73 gene (formerly known as HRPT2); to review this family with regard to modifications of guidelines for surveillance of hyperparathyroidism and other associated features in affected and at-risk relatives; and to discuss surgical recommendations in this syndrome.Methods: A review of English-language publications in PubMed and a review of GeneReviews were conducted pertaining to the subject of familial hyperparathyroidism. A case is described, and the family pedigree is discussed.Results: Review of the literature revealed that CDC73-related disorder has not previously been reported in patients younger than 10 years. This finding has been the basis for the recommendation for initiation of surveillance for disease manifestations at that age. Review of the family history of our current patient revealed a 7-year-old nephew with hypercalcemia attributable to primary hyperparathyroidism.Conclusion: Surveillance of hyperparathyroidism in affected persons and genetic testing of relatives at risk are currently recommended to start at 10 years of age. We recommend that these be conducted at a younger age, preferably 5 to 10 years before the earliest diagnosis of hyperparathyroidism within the family, and potentially at birth in families with a known mutation of the CDC73 gene, in light of the malignant potential of the disease.",
author = "Ariana Pichardo-Lowden and Andrea Manni and Brian Saunders and Maria Baker",
year = "2011",
month = "7",
day = "1",
doi = "10.4158/EP10337.RA",
language = "English (US)",
volume = "17",
pages = "602--609",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Familial hyperparathyroidism due to a germline mutation of the CDC73 gene

T2 - Implications for management and age-appropriate testing of relatives at risk

AU - Pichardo-Lowden, Ariana

AU - Manni, Andrea

AU - Saunders, Brian

AU - Baker, Maria

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Objective: To discuss the implications of a young age at diagnosis in a family member with hyperparathyroidism-jaw tumor syndrome, the youngest published case to date, due to a mutation of the CDC73 gene (formerly known as HRPT2); to review this family with regard to modifications of guidelines for surveillance of hyperparathyroidism and other associated features in affected and at-risk relatives; and to discuss surgical recommendations in this syndrome.Methods: A review of English-language publications in PubMed and a review of GeneReviews were conducted pertaining to the subject of familial hyperparathyroidism. A case is described, and the family pedigree is discussed.Results: Review of the literature revealed that CDC73-related disorder has not previously been reported in patients younger than 10 years. This finding has been the basis for the recommendation for initiation of surveillance for disease manifestations at that age. Review of the family history of our current patient revealed a 7-year-old nephew with hypercalcemia attributable to primary hyperparathyroidism.Conclusion: Surveillance of hyperparathyroidism in affected persons and genetic testing of relatives at risk are currently recommended to start at 10 years of age. We recommend that these be conducted at a younger age, preferably 5 to 10 years before the earliest diagnosis of hyperparathyroidism within the family, and potentially at birth in families with a known mutation of the CDC73 gene, in light of the malignant potential of the disease.

AB - Objective: To discuss the implications of a young age at diagnosis in a family member with hyperparathyroidism-jaw tumor syndrome, the youngest published case to date, due to a mutation of the CDC73 gene (formerly known as HRPT2); to review this family with regard to modifications of guidelines for surveillance of hyperparathyroidism and other associated features in affected and at-risk relatives; and to discuss surgical recommendations in this syndrome.Methods: A review of English-language publications in PubMed and a review of GeneReviews were conducted pertaining to the subject of familial hyperparathyroidism. A case is described, and the family pedigree is discussed.Results: Review of the literature revealed that CDC73-related disorder has not previously been reported in patients younger than 10 years. This finding has been the basis for the recommendation for initiation of surveillance for disease manifestations at that age. Review of the family history of our current patient revealed a 7-year-old nephew with hypercalcemia attributable to primary hyperparathyroidism.Conclusion: Surveillance of hyperparathyroidism in affected persons and genetic testing of relatives at risk are currently recommended to start at 10 years of age. We recommend that these be conducted at a younger age, preferably 5 to 10 years before the earliest diagnosis of hyperparathyroidism within the family, and potentially at birth in families with a known mutation of the CDC73 gene, in light of the malignant potential of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84860409929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860409929&partnerID=8YFLogxK

U2 - 10.4158/EP10337.RA

DO - 10.4158/EP10337.RA

M3 - Review article

C2 - 21324824

AN - SCOPUS:84860409929

VL - 17

SP - 602

EP - 609

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -